Antibodies, Assay Kits, cDNA, Clia Kits, Culture Cells, Devices, DNA, DNA Templates, DNA Testing, Elisa Kits, Enzymes, NATtrol, Panel, Particles, PCR, Pcr Kits, Peptides

Solvent Effects on the Self-Assembly of an Amphiphilic Polypeptide Incorporating α-Helical Hydrophobic Blocks

Solvent Effects on the Self-Assembly of an Amphiphilic Polypeptide Incorporating α-Helical Hydrophobic Blocks
Posted by Anna

Self assembly Biological molecules are important lines to understand the molecular basis of complex metabolic events. The presence of cosolvent in aqueous solution during the self-assembly process can promote the formation of a metasable intermediary that is trapped in Kina. In nature, cosolvents categories called osmolytes can work to strengthen hydrogen bond tissue in such a way that the original conditions of certain proteins are preferred, thus modulating their functions and stability. However, identifying COSOLVENTs that act as osmolytes in biomimetic applications, such as self-assignment of soft materials, remain challenging.

This work examines the effects of ethanol (ETOH) and acetonitrile (ACN) as cosolven at the self-assignment of Amphiphilic Polypeptide PSAR30- (L-LEU-AIB) 6 (S30L12), which combines α-helical hydrophobic blocks, in aqueous solution. The result gives direct observation of the morphological behavior of S30L12 as a function of solvent composition. Morfological transitions are investigated using electron microscope transmissions, while peptide molecular packaging is assessed using circular blocked analysis and evaluating membrane fluidity.

In the mixture of Etoh / H2O, EtOH strengthens the water hydrogen bond tissue, thus limiting the hydrophobic hydration of the S30L12 assembly and increasing hydrophobic interactions between assemblies. Conversely, ACN forms its own nanoclusters in water and on the hydrophobic core of peptide assemblies to stabilize the edges exposed to bulk water and increase assembly kinetics. Fourier Transform Infrared Analysis (FT-IR) shows that EtOH and ACN can modify biomaterial self assembly in the same way as protective or denaturant osmolyte.

Poisonous polypeptide production as fusion inside the recit cavity

This system was developed for efficient biosynthetic production of painsty polypeptides. A polipeptide target produced blends into the T. thermophilus tassel polpeptide in such a way that it is served in the purai cavity near the substrate binding surface. Such presentations allow the relieve potential issues instability, toxicity or peptide hydrophobicity that blends. Thermostilical thermostabilities can be used to separate a one-step from the host cell protein by heating. The target of polypeptides can be released by special chemical care amino acids.

In this study, Groel was adapted for special methionine cleavage with cyanogen bromide with a total metionine residue replacement to facilitate further purification of the polipeptide target. The procedure is simple, strong, and easy to improve. The capacity of this system to produce polypeptides that is difficult to express is shown by production in the bacterial system from one of the most powerful antibacterial peptides polyphemusin I.

Adenilaty Adenilaty Polypeptide Adenilaty Cyclase: Neuroprotective Peptides that Promise in Stroke

Searching for effective and effective care for acute strokes continues to be a global priority due to high mortality and morbidity. Terapeutic treatment currently has limited effects, making searches for imperative new care. Polypeptides in the pituitary clasp (Pacip) are established cytoprotective neuropeptide participating in various physiological and pathological activities of nerves, such as neuron proliferation, differentiation, and migration, and neuroprotection. This is considered a promising treatment in many neurological diseases.

Thus, PACAP bears potential as a new therapeutic strategy for stroke treatment. Here, we provide an overview that is related to the current PACAP knowledge, its receptors, and the potential role of neuroprotective in stroke settings, as well as various neuroprotecting mechanisms involving ion homeostasis, excitoxicity, cell edema, and oxidative stress ,, and cell death, and the route of giving Pacap.

Polypeptide Amyloid Islet & Beta Amyloid Peptide Role In Alzheimer’s Disease: Two Triggers, One Disease

Alzheimer’s disease (AD) is a neurodegenerative disorder that affects millions throughout the world. Because of the aging of the population, advertising events increase. Ad patients develop cognitive and dementia decreases, known features, requires permanent care. This raises the main socio-economic burden on the health care system because relatives and health workers are patients forced to overcome the increasing number of people affected. Despite the latest advances, the pathological mechanism of advertising is not fully understood.

Solvent Effects on the Self-Assembly of an Amphiphilic Polypeptide Incorporating α-Helical Hydrophobic Blocks

However, it is clear that the amyloid beta (Aβ) peptide, which forms amyloid plaque in the brain of AD patients, plays a key role. Type 2 diabetes, the most common form of diabetes, affects hundreds of millions of people globally. The amyloid polypeptide (IAPP) islet is a hormone produced and released by insulin in the β-β pancreas, with a key role of diabetes, because it helps regulate glucose levels and control adiposity and pursuit. Likewise with Aβ, IAPP is very amyloidogenic, produces intracellular amyloid deposits that cause β cell dysfunction and death.

BCL3 Peptide

7183P 0.05 mg
EUR 197.7
Description: (CT) BCL3 Peptide

BCL-10 Peptide

2161P 0.05 mg
EUR 197.7
Description: (NT) BCL-10 peptide

Bcl-2 Peptide

3335P 0.05 mg
EUR 197.7
Description: (NT) Bcl-2 peptide

Bcl-2 Peptide

3337P 0.05 mg
EUR 197.7
Description: (IN) Bcl-2 peptide

Bcl9L Peptide

6213P 0.05 mg
EUR 197.7
Description: (NT) Bcl9L peptide

BCL7A Peptide

45-325P 0.1 mg
EUR 405.6
Description: BCL7A Peptide

BCL2A1 Peptide

42-665P 0.1 mg
EUR 405.6
Description: (IN) BCL2A1 Peptide

BCL2L15 Peptide

43-245P 0.1 mg
EUR 405.6

BCL2L15 Peptide

42-323P 0.1 mg
EUR 405.6
Description: (IN) BCL2L15 Peptide

BCL10 Blocking Peptide

DF6246-BP 1mg
EUR 234

BCL10 Blocking Peptide

DF3606-BP 1mg
EUR 234

BCL11A Blocking Peptide

AF7561-BP 1mg
EUR 234

BCL11A Blocking Peptide

33R-10043 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL11A antibody, catalog no. 70R-8372

BCL11A Blocking Peptide

33R-6490 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL11A antibody, catalog no. 70R-8336

BCL11A Blocking Peptide

DF7345-BP 1mg
EUR 234

BCL11B Blocking Peptide

DF2464-BP 1mg
EUR 234

BCL2 Blocking Peptide

20-abx062289
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

Bcl2 Blocking Peptide

33R-10602 50 ug
EUR 229.2
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bcl2 antibody, catalog no. 70R-11571

BCL3 Blocking Peptide

33R-10746 50 ug
EUR 229.2
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL3 antibody, catalog no. 70R-11804

BCL9 Blocking Peptide

DF12515-BP 1mg
EUR 234

BCL2 Blocking Peptide

20-abx161300
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

BCL2 Blocking Peptide

20-abx161556
  • EUR 727.20
  • EUR 1713.60
  • 1 mg
  • 5 mg

BCL9L Blocking Peptide

AF7915-BP 1mg
EUR 234

BCL7A Blocking Peptide

33R-1704 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL7A antibody, catalog no. 70R-3771

BCL6B Blocking Peptide

33R-5338 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL6B antibody, catalog no. 70R-8459

BCL7A Blocking Peptide

33R-7534 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL7A antibody, catalog no. 70R-3765

BCL6B Blocking Peptide

DF9075-BP 1mg
EUR 234

BCL7A Blocking Peptide

DF4737-BP 1mg
EUR 234

BCL7B Blocking Peptide

DF2586-BP 1mg
EUR 234

BCL7C Blocking Peptide

DF2587-BP 1mg
EUR 234

BCL2A1 Blocking Peptide

33R-2930 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2A1 antibody, catalog no. 70R-10524

BCL2L1 Blocking Peptide

33R-8657 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L1 antibody, catalog no. 20R-1065

BCL2L1 Blocking Peptide

33R-5547 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L1 antibody, catalog no. 70R-10444

BCL2L1 Blocking Peptide

33R-6481 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L1 antibody, catalog no. 70R-10443

BCL2A1 Blocking Peptide

DF7652-BP 1mg
EUR 234

BCL2L1 Blocking Peptide

DF6015-BP 1mg
EUR 234

BCL2L2 Blocking Peptide

DF6292-BP 1mg
EUR 234

BCL2L13 Blocking Peptide

33R-9493 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L13 antibody, catalog no. 70R-10451

BCL2L12 Blocking Peptide

33R-4918 100 ug
EUR 216
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BCL2L12 antibody, catalog no. 70R-10366

BCL2L14 Blocking Peptide

DF9220-BP 1mg
EUR 234

BCL2L12 Blocking Peptide

DF3830-BP 1mg
EUR 234

BCL2L13 Blocking Peptide

DF6248-BP 1mg
EUR 234

BCL2L10 Blocking Peptide

DF2276-BP 1mg
EUR 234

BCL2L13 Blocking Peptide

DF2649-BP 1mg
EUR 234

BCL-3 Blocking Peptide

AF7756-BP 1mg
EUR 234

Bcl-2 Blocking Peptide

3033BP-50 each
EUR 183.6

Bcl-3 Blocking Peptide

3407BP-50 each
EUR 183.6

Bcl-6 Blocking Peptide

3408BP-50 each
EUR 183.6

Bcl-2 Blocking Peptide

BF9103-BP 1mg
EUR 234

BCL-2 Blocking Peptide

AF0769-BP 1mg
EUR 234

Bcl-2 Blocking Peptide

AF4700-BP 1mg
EUR 234

BCL-2 Blocking Peptide

AF6139-BP 1mg
EUR 234

BCL-3 Blocking Peptide

DF10317-BP 1mg
EUR 234

BCLAF1 Peptide

8373P 0.05 mg
EUR 197.7
Description: BCLAF1 Peptide

BCL2 (pT56) Blocking Peptide

20-abx061740
  • EUR 360.00
  • EUR 594.00
  • 1 mg
  • 5 mg

BCL2 (pS70) Blocking Peptide

20-abx061755
  • EUR 360.00
  • EUR 594.00
  • 1 mg
  • 5 mg

BCL2 (pS70) Blocking Peptide

20-abx062038
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

BCL2 (pT69) Blocking Peptide

20-abx062288
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

BCL2 (pS87) Blocking Peptide

20-abx161301
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

Bcl-B Peptide

3163P 0.05 mg
EUR 197.7
Description: (IN) Bcl-B peptide

Bcl-G Peptide

3165P 0.05 mg
EUR 197.7
Description: (NT) Bcl-G peptide

Bcl-xL Peptide

3341P 0.05 mg
EUR 197.7
Description: (CT) Bcl-xL peptide

Bad / Bcl-2-like 8 Peptide

3343P 0.05 mg
EUR 197.7
Description: (CT) Bad / Bcl-2-like 8 peptide

Bcl-rambo Peptide

3023P 0.05 mg
EUR 197.7
Description: (IN) Bcl-rambo peptide

BCLW Blocking Peptide

20-abx062039
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

BclB Blocking Peptide

33R-10884 50 ug
EUR 229.2
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of BclB antibody, catalog no. 70R-12009

BCLW Blocking Peptide

DF3607-BP 1mg
EUR 234

BCLX Blocking Peptide

20-abx161558
  • EUR 727.20
  • EUR 1713.60
  • 1 mg
  • 5 mg

BCLAF1 Blocking Peptide

20-abx063617
  • EUR 326.40
  • EUR 493.20
  • 1 mg
  • 5 mg

BCLAF1 Blocking Peptide

DF3828-BP 1mg
EUR 234

bcl-2-related protein A1 Peptide

43-369P 0.1 mg
EUR 405.6

Bcl xL Blocking Peptide

33R-10466 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bcl xL antibody, catalog no. 20R-1516

Bcl 6 Blocking Peptide

33R-10485 50 ug
EUR 418.8
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bcl 6 antibody, catalog no. 20R-1556

Bcl-B Blocking Peptide

3695BP-50 each
EUR 183.6

Control/Blocking peptide Human BCL-2

BCL11-C 100 ug
EUR 196.8

Control/Blocking peptide Mouse BCL-2

BCL21-C 100 ug
EUR 196.8

BCL-XL Blocking Peptide

AF6414-BP 1mg
EUR 234

BCL-XL Blocking Peptide

AF6415-BP 1mg
EUR 234

Bcl-xL Blocking Peptide

33R-10707 50 ug
EUR 229.2
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Bcl-xL antibody, catalog no. 70R-11750

Bcl-xL Blocking Peptide

3312BP-50 each
EUR 183.6

BCLX (pS62) Blocking Peptide

20-abx161302
  • EUR 376.80
  • EUR 610.80
  • 1 mg
  • 5 mg

BCLX (pT47) Blocking Peptide

20-abx161557
  • EUR 1062.00
  • EUR 2548.80
  • 1 mg
  • 5 mg

Bcl-Rambo Blocking Peptide

3671BP-50 each
EUR 183.6

TKD Peptide (Hsp70 Peptide) (Hsp70 Peptide)

SIH-118A 1 mg
EUR 374.4
Description: The substance TKD Peptide (Hsp70 Peptide) is a hsp70 peptide. It is synthetically produced and has a purity of >98%. The pure substance is solid which is In aqueous solution.

TKD Peptide (Hsp70 Peptide): FITC (Hsp70 Peptide)

SIH-119A 1 mg
EUR 430.8
Description: The substance TKD Peptide (Hsp70 Peptide): FITC is a hsp70 peptide. It is synthetically produced and has a purity of >98%. The pure substance is solid which is In aqueous solution.

TKD Peptide (Hsp70 Peptide)

abx076809-1mg 1 mg
EUR 594

Rat Peptide YY (PYY) Peptide

20-abx068453
  • EUR 744.00
  • EUR 326.40
  • EUR 2230.80
  • EUR 878.40
  • EUR 543.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Connecting Peptide (C-Peptide) Peptide

abx670072-05mg 0.5 mg
EUR 678

Human Peptide YY (PYY) Peptide

20-abx068451
  • EUR 693.60
  • EUR 309.60
  • EUR 2013.60
  • EUR 811.20
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Peptide YY (PYY) Peptide

20-abx068452
  • EUR 710.40
  • EUR 309.60
  • EUR 2131.20
  • EUR 844.80
  • EUR 526.80
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

TKD Peptide (Hsp70 Peptide) (FITC)

abx076810-1mg 1 mg
EUR 678

Rat Connecting Peptide (C-Peptide) Peptide (OVA)

20-abx651058
  • EUR 510.00
  • EUR 276.00
  • EUR 1378.80
  • EUR 594.00
  • EUR 376.80
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Dog Peptide YY (PYY) Peptide (OVA)

20-abx651198
  • EUR 427.20
  • EUR 260.40
  • EUR 1178.40
  • EUR 526.80
  • EUR 343.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Pig Peptide YY (PYY) Peptide (OVA)

20-abx651200
  • EUR 427.20
  • EUR 260.40
  • EUR 1178.40
  • EUR 526.80
  • EUR 343.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Rat Peptide YY (PYY) Peptide (OVA)

20-abx651201
  • EUR 427.20
  • EUR 260.40
  • EUR 1178.40
  • EUR 526.80
  • EUR 343.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Peptide YY (PYY) Peptide (OVA)

20-abx651199
  • EUR 427.20
  • EUR 260.40
  • EUR 1178.40
  • EUR 526.80
  • EUR 343.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Peptide YY (PYY) Peptide (OVA)

20-abx651848
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Peptide 810

H-2586.0001 1.0mg
EUR 529.2
Description: Sum Formula: C59H91N13O17S; CAS# [156371-22-1]

Peptide 810

H-2586.0005 5.0mg
EUR 2010
Description: Sum Formula: C59H91N13O17S; CAS# [156371-22-1]

Peptide 401

HY-12537 500ug
EUR 523.2

Rat Galanin Like Peptide (GALP) Peptide

20-abx650475
  • EUR 777.60
  • EUR 326.40
  • EUR 2364.00
  • EUR 927.60
  • EUR 560.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Caspase peptide-17(Caspase peptide-17)

QY-E05408 96T
EUR 433.2

BCL6 siRNA

20-abx908994
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

BCL6 siRNA

20-abx908995
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

Formyl Peptide Receptor-like 2 Peptide

43-293P 0.1 mg
EUR 405.6

Dog Brain Natriuretic Peptide (BNP) Peptide

20-abx065598
  • EUR 1062.00
  • EUR 393.60
  • EUR 3400.80
  • EUR 1262.40
  • EUR 727.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Pig Brain Natriuretic Peptide (BNP) Peptide

20-abx065601
  • EUR 994.80
  • EUR 376.80
  • EUR 3199.20
  • EUR 1195.20
  • EUR 693.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Rat Brain Natriuretic Peptide (BNP) Peptide

20-abx652109
  • EUR 910.80
  • EUR 360.00
  • EUR 2865.60
  • EUR 1095.60
  • EUR 644.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Canine C Peptide(C Peptide) ELISA Kit

ECA0028 96T
EUR 681.12
Description: Method of detection: Coated with Antigen, Competitive ELISA;Reacts with: Canine;Sensitivity: 0.469 ng/ml

Rat Atrial Natriuretic Peptide (ANP) Peptide

20-abx065483
  • EUR 693.60
  • EUR 309.60
  • EUR 2064.00
  • EUR 828.00
  • EUR 510.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Rat Atrial Natriuretic Peptide (ANP) Peptide

20-abx065484
  • EUR 777.60
  • EUR 326.40
  • EUR 2331.60
  • EUR 910.80
  • EUR 560.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Rat Atrial Natriuretic Peptide (ANP) Peptide

20-abx065486
  • EUR 777.60
  • EUR 326.40
  • EUR 2331.60
  • EUR 910.80
  • EUR 560.40
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Cow Atrial Natriuretic Peptide (ANP) Peptide

20-abx166288
  • EUR 878.40
  • EUR 343.20
  • EUR 2766.00
  • EUR 1062.00
  • EUR 627.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain Natriuretic Peptide (BNP) Peptide

20-abx065599
  • EUR 878.40
  • EUR 343.20
  • EUR 2766.00
  • EUR 1062.00
  • EUR 627.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Brain Natriuretic Peptide (BNP) Peptide

20-abx065600
  • EUR 895.20
  • EUR 360.00
  • EUR 2798.40
  • EUR 1062.00
  • EUR 627.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Mouse Brain Natriuretic Peptide (BNP) Peptide

20-abx065602
  • EUR 895.20
  • EUR 360.00
  • EUR 2798.40
  • EUR 1062.00
  • EUR 627.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Brain natriuretic peptide (BNP) Peptide

abx670010-01mg 0.1 mg
EUR 360

Human Osteogenic Growth Peptide (OGP) Peptide

20-abx652290
  • EUR 661.20
  • EUR 292.80
  • EUR 1914.00
  • EUR 777.60
  • EUR 493.20
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

BCL6 antibody

10R-1574 100 ug
EUR 614.4
Description: Mouse monoclonal BCL6 antibody

BCL6 Antibody

25523-100ul 100ul
EUR 468

BCL6 Antibody

37150-100ul 100ul
EUR 302.4

BCL6 antibody

70R-11805 100 ug
EUR 552
Description: Rabbit polyclonal BCL6 antibody

BCL6 Antibody

6985-002mg 0.02 mg
EUR 206.18
Description: BCL6 Antibody: BCL6 was first identified as a proto-oncogene in diffuse large B cell lymphoma. BCL6, a transcriptional repressor, plays an important role in lymphomagenesis. It binds Stat recognition-like DNA elements and is required for affinity maturation of mature B cells in germinal centers and Th1/Th2 differentiation, a process that critically depends on BCL6-mediated transcriptional repression of p53. BCL6 is a pharmacological target for eradication of leukemia-initiating cells in chronic myeloid leukemia (CML).

BCL6 Antibody

6985-01mg 0.1 mg
EUR 523.7
Description: BCL6 Antibody: BCL6 was first identified as a proto-oncogene in diffuse large B cell lymphoma. BCL6, a transcriptional repressor, plays an important role in lymphomagenesis. It binds Stat recognition-like DNA elements and is required for affinity maturation of mature B cells in germinal centers and Th1/Th2 differentiation, a process that critically depends on BCL6-mediated transcriptional repression of p53. BCL6 is a pharmacological target for eradication of leukemia-initiating cells in chronic myeloid leukemia (CML).

Bcl6 antibody

70R-34469 100 ug
EUR 392.4
Description: Rabbit polyclonal Bcl6 antibody

Bcl6 Antibody

ABD2903 100 ug
EUR 525.6

BCL6 Antibody

ABD7508 100 ug
EUR 525.6

BCL6 Antibody

1-CSB-PA005439
  • EUR 266.40
  • EUR 234.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000

BCL6 Antibody

1-CSB-PA171912
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;ELISA:1:1000-1:2000, WB:1:200-1:1000, IHC:1:25-1:100

BCL6 Antibody

1-CSB-PA040220
  • EUR 266.40
  • EUR 234.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/10000

BCL6 Antibody

1-CSB-PA040221
  • EUR 266.40
  • EUR 234.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/40000

BCL6 Antibody

1-CSB-PA908823
  • EUR 380.40
  • EUR 292.80
  • 100ul
  • 50ul
Description: A polyclonal antibody against BCL6. Recognizes BCL6 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:25-1:100

BCL6 Antibody

F50351-0.08ML 0.08 ml
EUR 140.25
Description: BCL6 is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of START-dependent IL-4 responses of B cells. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors.

BCL6 Antibody

F50351-0.4ML 0.4 ml
EUR 322.15
Description: BCL6 is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of START-dependent IL-4 responses of B cells. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors.

BCL6 Antibody

F40298-0.08ML 0.08 ml
EUR 140.25
Description: The protein encoded by this gene is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of START-dependent IL-4 responses of B cells. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors. This gene is found to be frequently translocated and hypermutated in diffuse large-cell lymphoma (DLCL), and may be involved in the pathogenesis of DLCL. Alternatively spliced transcript variants encoding different protein isoforms have been found for this gene.

BCL6 Antibody

F42687-0.08ML 0.08 ml
EUR 140.25
Description: BCL6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4+ T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53-dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH-dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation. [UniProt]

BCL6 Antibody

F42687-0.4ML 0.4 ml
EUR 322.15
Description: BCL6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. An important function is to allow GC B-cells to proliferate very rapidly in response to T-cell dependent antigens and tolerate the physiological DNA breaks required for immunglobulin class switch recombination and somatic hypermutation without inducing a p53/TP53-dependent apoptotic response. In follicular helper CD4+ T-cells (T(FH) cells), promotes the expression of T(FH)-related genes but inhibits the differentiation of T(H)1, T(H)2 and T(H)17 cells. Also required for the establishment and maintenance of immunological memory for both T- and B-cells. Suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs binding on certain target genes, such as CCL2 and CCND2. In response to genotoxic stress, controls cell cycle arrest in GC B-cells in both p53/TP53-dependedent and -independent manners. Besides, also controls neurogenesis through the alteration of the composition of NOTCH-dependent transcriptional complexes at selective NOTCH targets, such as HES5, including the recruitment of the deacetylase SIRT1 and resulting in an epigenetic silencing leading to neuronal differentiation. [UniProt]

Bcl6 Antibody

V3457-100UG 100 ug
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3457-20UG 20 ug
EUR 153.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3457SAF-100UG 100 ug
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3495-100UG 100 ug
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3495-20UG 20 ug
EUR 153.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3495SAF-100UG 100 ug
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3496-100UG 100 ug
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3496-20UG 20 ug
EUR 153.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3496SAF-100UG 100 ug
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3712-100UG 100 ug
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3712-20UG 20 ug
EUR 153.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3712SAF-100UG 100 ug
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3805-100UG 100 ug
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3805-20UG 20 ug
EUR 153.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V3805SAF-100UG 100 ug
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V7340-100UG 100 ug
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V7340-20UG 20 ug
EUR 153.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V7340IHC-7ML 7 ml
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V7340SAF-100UG 100 ug
EUR 349.3
Description: Antibody to Bcl-6 is helpful in a number of diagnostic settings: First, in the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show Bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. Second, Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, Bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. Third, Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V7350-100UG 100 ug
EUR 349.3
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt]

Bcl6 Antibody

V7350-20UG 20 ug
EUR 153.3
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt]

Bcl6 Antibody

V7350IHC-7ML 7 ml
EUR 349.3
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt]

Bcl6 Antibody

V7350SAF-100UG 100 ug
EUR 349.3
Description: Bcl6 is a transcriptional repressor mainly required for germinal center (GC) formation and antibody affinity maturation which has different mechanisms of action specific to the lineage and biological functions. Forms complexes with different corepressors and histone deacetylases to repress the transcriptional expression of different subsets of target genes. Represses its target genes by binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing the transcriptional activity of transcription factors. In GC B-cells, represses genes that function in differentiation, inflammation, apoptosis and cell cycle control, also autoregulates its transcriptional expression and up-regulates, indirectly, the expression of some genes important for GC reactions, such as AICDA, through the repression of microRNAs expression, like miR155. [UniProt]

Bcl6 Antibody

V2840-100UG 100 ug
EUR 349.3
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V2840-20UG 20 ug
EUR 153.3
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V2840IHC-7ML 7 ml
EUR 349.3
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

V2840SAF-100UG 100 ug
EUR 349.3
Description: Recognizes a protein of 95kDa, which is identified as Bcl-6. Antibody to bcl-6 is helpful in a number of diagnostic settings: (1) In the differential diagnosis of small B-cell lymphoma. Follicular lymphoma will show bcl-6 (and CD10) positivity whereas other small B-cell lymphomas are usually negative. (2) Bcl-6 is an important prognostic marker in diffuse large B-cell lymphomas (DLBCL), where CD10, bcl-6 and MUM1/IRF4 are used to identify germinal center and activated B-cell phenotypes. (3) Bcl-6 can be valuable in distinguishing classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The Reed-Sternberg cells of classical Hodgkin lymphoma are bcl-6 negative whereas the large (L&H) cells of NLPHL are bcl-6 positive. In contrast, anti-Bcl-6 rarely stains mantle-cell lymphoma and MALT lymphoma.

Bcl6 Antibody

RQ4637 100ug
EUR 356.15
Description: B-cell lymphoma 6 protein is a protein that in human is encoded by the BCL6 gene. Like BCL2, BCL3, BCL5, BCL7A, BCL9 and BCL10, it has clinical significance in lymphoma. The protein encoded by this gene is an evolutionarily conserved zinc finger transcription factor and contains an N-terminal POZ/BTB domain. This protein acts as a sequence-specific repressor of transcription and has been shown to modulate the STAT-dependent Interleukin 4 (IL-4) responses of B cells. This protein can interact with several corepressor complexes to inhibit transcription. This gene is found to be frequently translocated and hypermutated in diffuse large B cell lymphoma (DLBCL) and contributes to the pathogenesis of DLBCL. An exon 7 skipping splice variant encodes a shorter form of the protein which lacks the first two zinc fingers of the DNA binding domain.

BCL6 Antibody

E38PA3803 100ul
EUR 225
Description: Available in various conjugation types.

Now it is clear that IAPP can also have a pathological role in AD, reducing cognitive function. IAPP harms blood-brain barriers, directly interacting and co-deposits with Aβ, promoting dementia associated with diabetes. IAPP can cause metabolic dysfunction in the brain, which leads to other diabetes advertisements. Thus, here we discuss the IAPP associations with diabetes, Aβ and dementia, in the context of what we specify “brain diabetes phenotype”. The hypothesis such approach helps establish a conceptual framework for IAPP-based drugs in the future against AD.

Related Post

Leave A Comment